Table 2 Interval of metachronous ovarian metastasis and differentiation of tumors of the 177 patients
Colorectum (n = 68) | Stomach (n = 61) | Appendix (n = 12) | Biliary Tract (n = 7) | Pancreas (n = 7) | Breast (n = 6) | Small intestine (n = 5) | Lung (n = 3) | Bladder (n = 2) | Unknowna (n = 6) | |
|---|---|---|---|---|---|---|---|---|---|---|
Chronological sequence Synchronous | 40 (58.8%) | 30 (49.2%) | 10 (83.3%) | 2 (28.6%) | 4 (57.1%) | – | 2 (40.0%) | 1 (33.3%) | 1 (50.0%) | 6 (100.0%) |
Metachronous | 28 (41.2%) | 31 (50.8%) | 2 (16.7%) | 5 (71.4%) | 3 (42.9%) | 6 (100.0%) | 3 (60.0%) | 2 (66.7%) | 1 (50.0%) | – |
Median intervalb (range, months) | 12.5 (2–40) | 20 (1.5–240) | 95, 95 | 51 (12–73) | 112 (19–115) | 54 (7–81) | 18 (12–34) | 4, 48 | 135 | – |
Differentiation Well | 10 (14.7%) | – | 4 (33.3%) | – | 3 (42.9%) | – | – | – | – | – |
Moderate | 42 (61.8%) | 6 (9.8%) | 4 (33.3%) | 3 (42.9%) | 2 (28.6%) | – | 2 (40.0%) | – | 1 (50.0%) | 2 (33.3%) |
Poor/undifferentiated | 16 (23.5%) | 52 (85.2%) | 4 (33.3%) | 1 (14.3%) | 1 (14.3%) | 5 (83.3%) | 3 (60.0%) | 3 (100.0%) | 0 (0%) | 2 (33.3%) |
Not available | 0 (0%) | 3 (4.9%) | – | 3 (42.9%) | 1 (14.3%) | 1 (16.7%) | – | – | 1 (50.0%) | 2 (33.3%) |